3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Prostatic Neoplasms
29
Breast Neoplasms
10
Neoplasms
2
Stage II Prostate Adenocarcinoma
1
Salivary Gland Neoplasms
1
Prostatectomy
1
Prostate Cancer Metastatic Disease
1
Ovarian Neoplasms
1
Oligometastatic Prostate Carcinoma
1
Metastatic Castration-resistant Prostate Cancer
1
Highly Endocrine Responsive Operable Breast Cancer
1
Cardiovascular Diseases
1
Anatomic Stage III Breast Cancer AJCC v8
1
Interventions
Paclitaxel
134
Carboplatin
129
Bevacizumab
86
Gemcitabine
45
pembrolizumab
37
olaparib
33
Cisplatin
30
liposomal doxorubicin
29
Docetaxel
29
Cyclophosphamide
29
Topotecan
28
niraparib
27
Taxes
20
Etoposide
18
Filgrastim
16
Doxorubicin
16
Immunoglobulin G
15
Disulfides
15
apatinib
12
Letrozole
12
Albumin-Bound Paclitaxel
12
Drug Therapy
11
fluzoparib
10
fludarabine
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
10
durvalumab
9
Nivolumab
9
pazopanib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ovarian Neoplasms
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT04931342
2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2
Active not recruiting
176 enrolled